Head to Head Analysis: ENDRA Life Sciences (NASDAQ:NDRA) versus Echo Therapeutics (NASDAQ:ECTE)

Share on StockTwits

ENDRA Life Sciences (NASDAQ:NDRA) and Echo Therapeutics (OTCMKTS:ECTE) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk and valuation.

Insider & Institutional Ownership

17.2% of ENDRA Life Sciences shares are held by institutional investors. 11.4% of ENDRA Life Sciences shares are held by insiders. Comparatively, 7.0% of Echo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares ENDRA Life Sciences and Echo Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ENDRA Life Sciences $10,000.00 888.42 -$9.80 million ($2.10) -0.64
Echo Therapeutics N/A N/A N/A N/A N/A

Echo Therapeutics has lower revenue, but higher earnings than ENDRA Life Sciences.

Volatility & Risk

ENDRA Life Sciences has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500. Comparatively, Echo Therapeutics has a beta of 8.9, suggesting that its stock price is 790% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for ENDRA Life Sciences and Echo Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ENDRA Life Sciences 0 0 3 0 3.00
Echo Therapeutics 0 0 0 0 N/A

ENDRA Life Sciences presently has a consensus target price of $6.00, indicating a potential upside of 347.76%. Given ENDRA Life Sciences’ higher possible upside, analysts plainly believe ENDRA Life Sciences is more favorable than Echo Therapeutics.

Profitability

This table compares ENDRA Life Sciences and Echo Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ENDRA Life Sciences N/A -326.97% -233.06%
Echo Therapeutics N/A N/A N/A

Summary

ENDRA Life Sciences beats Echo Therapeutics on 5 of the 8 factors compared between the two stocks.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences Inc. develops medical imaging technology based on the thermos-acoustic effect that improves the sensitivity and specificity of clinical ultrasound. It offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. It also offers Nexus-128 system that combines light-based thermos-acoustics and ultrasound to address the imaging needs of researchers studying disease models in pre-clinical applications. ENDRA Life Sciences Inc. has collaborative research agreement with General Electric Company. The company was incorporated in 2007 and is based in Ann Arbor, Michigan.

Echo Therapeutics Company Profile

Echo Therapeutics, Inc. engages in the development of transdermal skin permeation and diagnostic medical devices for wearable-health consumer and diabetes outpatient markets. It is developing continuous glucose monitoring (CGM) system, a needle-free wireless continuous glucose monitoring system in a hospital setting in the European Union. The company has a licensing agreement with Ferndale Pharma Group, Inc. to develop, manufacture, distribute, and market devices for skin preparation prior to the application of topical anesthetics or analgesics prior to a range of needle-based medical procedures in North America, the United Kingdom, South America, Australia, New Zealand, Switzerland, and other portions of the European Community. In addition, it has a license agreement with Handok Pharmaceuticals Co., Ltd. to develop, use, market, import, and sell CGM to medical facilities and individual consumers in South Korea; and a license, development, and commercialization agreement with Medical Technologies Innovation Asia, Ltd to research, develop, manufacture, and use CGM in the People's Republic of China, Hong Kong, Macau, and Taiwan. The company was founded in 1989 and is headquartered in Iselin, New Jersey.

Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Obsidian Energy  Rating Lowered to Sell at Zacks Investment Research
Obsidian Energy Rating Lowered to Sell at Zacks Investment Research
PETROLEO BRASIL/ADR  Rating Lowered to Sell at ValuEngine
PETROLEO BRASIL/ADR Rating Lowered to Sell at ValuEngine
Plains GP  Rating Increased to Buy at Zacks Investment Research
Plains GP Rating Increased to Buy at Zacks Investment Research
Bank of America Lowers Palo Alto Networks  Price Target to $275.00
Bank of America Lowers Palo Alto Networks Price Target to $275.00
Zacks Investment Research Downgrades Navigator  to Strong Sell
Zacks Investment Research Downgrades Navigator to Strong Sell
Pembina Pipeline  Stock Rating Upgraded by Zacks Investment Research
Pembina Pipeline Stock Rating Upgraded by Zacks Investment Research


© 2006-2019 Ticker Report